Lilly - Up-to-date treatment of spondyloarthritis: Innovation becoming standard of care


Industry room 1
English
Satellite Symposia
03 June 2021 17:30 - 19:00

Eli Lilly & Company welcomes you to this virtual satellite symposium entitled “Up-to-date treatment of spondyloarthritis: Innovation becoming standard of care”. These presentations are in line with the EMA-approved label of Ixekizumab. For the latest approved Ixekizumab label please check the Lilly company profile on this platform and the EMA website.

Learning Objectives:

  • To inform on the most up to date PsA recommendations and to present available evidence supporting the use of Ixekizumab in PsA and axSpA as well as use in clinical practice
  • To illustrate how treatment decisions are made based on state-of-the-art knowledge and applicable current guidelines (or treatment recommendations)
  • To present the most updated results on ixekizumab efficacy and safety for the management of patients with axial spondyloarthritis and to discuss the different therapeutic options through clinical cases

Chair(s) of the session

Dr. Sofia Ramiro, Netherlands

Presentations

Title Time Calendar .ics
Welcome and introduction
03 June 2021 17:30 - 17:35 .ics
Clinical decision making for the management of patients with psoriatic arthritis
03 June 2021 17:35 - 17:55 .ics
New treatment options for patients with axial spondyloarthritis: From clinical trials to daily practice
03 June 2021 17:55 - 18:15 .ics
Panel discussion and live Q&A
03 June 2021 18:15 - 18:55 .ics
Summary and close
03 June 2021 18:55 - 19:00 .ics